Pursuant to the provisions of the Rules of the Ljubljana Stock Exchange, d.d. Ljubljana, and Articles 136 and 137 of the Financial Instrument Market Act (ZTFI-1), the company  SALUS, Ljubljana, d.d., Litostrojska cesta 46a, Ljubljana, herby publishes information on the operations of SALUS, Ljubljana, d.d. and the SALUS Group for the first half of 2026.

Double-digit growth
SALUS Group continued to grow across all levels in the first half, with profit growing faster than revenue. Revenue reached EUR 399.0 million, up 18 percent year on year, while net profit reached EUR 10.3 million, up by a little more than a fifth. Per share, this translates into EUR 1.23 of net profit, compared with EUR 1.00 in the first half of last year.

Regular EBITDA rose by 22 percent to EUR 16,9 million and operating profit from regular operations by 24 percent to EUR 12,5 million.

The result was driven by higher business volumes, a changed sales mix and the contribution of companies brought into the Group in recent years. These now account for a significant part of the Group's business and have consistently contributed to revenue growth and profitability since joining.

We enable growth for each company that joins the Group through shared infrastructure, regional reach and relationships with international manufacturers. We continue in this direction with the sale and purchase agreement for the business share of Farmedica d.o.o. signed in June 2026, concluded under suspensive conditions.

First choice for commercialization and distribution in the CEE region

The results confirm the Group's direction of development. "The first half confirms that we are on the right path. Growth matters, but growing in a considered way matters even more. Behind these figures stands the work of our colleagues across all of the Group's markets, in warehouses, on the road and in offices, who make sure every day that pharmaceuticals and medical devices reach the patient when the patient needs them. I am glad that together we are delivering on our mission, to improve people's lives by providing state-of-the-art pharmaceuticals and medical devices," said Žiga Hieng, President of the Management Board of SALUS, Ljubljana, d.d.

Looking ahead

For the 2026 financial year, SALUS Group expects to generate approximately EUR 812 million in net sales revenue, EUR 19 million in operating profit from regular operations, EUR 28 million in regular EBITDA and EUR 15.5 million in net profit. The plan follows the Group's strategy, which is built on consolidating its position in the Slovenian market and internationalising its operations across the CEE region.

This announcement will be available on our website from 28 August 2026 until the expiry of the legally prescribed publication period.